Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brain cancer vaccine - Northwest Biotherapeutics

Drug Profile

Brain cancer vaccine - Northwest Biotherapeutics

Alternative Names: DCVax-Brain; DCVax-Brain personalised immune therapy - Northwest Biotherapeutics; DCVax-L; DCVax-L (Glioblastoma)

Latest Information Update: 23 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma

Most Recent Events

  • 19 Nov 2018 Updated interim efficacy data from a phase III trial in Glioblastoma released by Northwest Biotherapeutics
  • 29 May 2018 Interim efficacy and adverse events data from a phase III trial in Glioblastoma released by Northwest Biotherapeutics
  • 18 Jan 2018 Northwest Biotherapeutics' brain cancer vaccine is still at phase III development stage for Glioblastoma (Newly diagnosed) in Canada, Germany, USA and United Kingdom (Intradermal) (Northwest Biotherapeutics website, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top